Comprehensive next-generation sequencing data and use of novel drugs in Acute Leukemia patients
Molecularly directed treatment options represent a significant advance in the field of acute myeloid leukemia (AML). The latter highlights the importance of next-generation sequencing (NGS) as a backbone of the clinical decision-making process, both at diagnosis and at time of relapse. Today, NGS allows for assessing the unique clonal hierarchy of individual AML patients, leading to tailored treatment approaches, thereby providing improved outcomes. Identifying “druggable” mutations paves the way for the use of novel targeted therapies. This may represent an attractive bridging approach for reinduction before allogeneic hematopoietic stem cell transplantation. With this background, the ALWP is launching a major project aiming to collect comprehensive NGS data, and use of novel drugs before and after stem cell transplantation, in AL patients reported to the EBMT registry. In light of the recent improvements in AL treatment options, collecting such data will allow to generate new knowledge to further advance the field.
The invitation and data collection has been launched recently, and eligible patients are adults patients transplanted (allogeneic or autologous transplantation) for AML or ALL between 2013 and 2019.
The comprehensive list of patients who are potential candidates for inclusion in the study has been sent, however the number of eligible patients may be much lower depending on the use of «NGS» and «novel drugs».
For any further information please contact Mohamed Houhou at mohamed.houhou@upmc.fr who is in charge of the management of this project.
We would highly appreciate your contribution to this important new study.